PRESS RELEASE

STRONG Q3 REVENUE GROWTH, UP 8% AT CONSTANT EXCHANGE RATES
2026 GUIDANCE CONFIRMED

- **REVENUES:** IN Q3, **€308 MILLION**, UP 8% *AT CONSTANT EXCHANGE RATES* (+10% *AT CURRENT EXCHANGE RATES*), DRIVEN BY ACCELERATING GROWTH ACROSS ALL BUSINESS LINES; IN THE FIRST NINE MONTHS, **€910 MILLION**, UP 3% *AT CONSTANT EXCHANGE RATES* (+1% *AT CURRENT EXCHANGE RATES*) COMPARED WITH THE SAME PERIOD OF THE PREVIOUS YEAR
- **EBITDA[1] ADJUSTED[2]:** IN Q3, **€103 MILLION**, REPRESENTING 34% OF REVENUES *AT CONSTANT EXCHANGE RATES* (33% *AT CURRENT EXCHANGE RATES*); IN THE FIRST NINE MONTHS, **€297 MILLION**, REPRESENTING 33% OF REVENUES *AT* BOTH *CONSTANT* AND *CURRENT EXCHANGE RATES*
- SUCCESSFULLY COMPLETED THE SHARE BUYBACK PROGRAM, UNDER WHICH DIASORIN ACQUIRED 3,790,952 TREASURY SHARES, REPRESENTING 6.78% OF THE SHARE CAPITAL, FOR A TOTAL CONSIDERATION OF €249,999,986.67
- **2026 GUIDANCE CONFIRMED** (BASED ON 2025 CONSTANT EXCHANGE RATES), WITH REVENUE GROWTH EXPECTED BETWEEN +5% AND +6% AND AN ADJUSTED EBITDA MARGIN BETWEEN 32% AND 33%.

Saluggia (Italy), November 12, 2026 – The Board of Directors of Diasorin S.p.A. reviewed and approved the Group's consolidated financial results for the first nine months of 2026.

.

TABLES OF RESULTS[2]

Amounts in millions of euros	Q3		change		
	2025	2026	amount	% @ current	% @ CER
Revenues	**280.4**	**308.0**	**+28**	***+10%***	***+8%***
Immunodiagnostics	*198.6*	*212.6*	*+14*	*+7%*	*+5%*
Molecular Diagnostics	*45.1*	*50.9*	*+6*	*+13%*	*+11%*
Licensed Technologies	*36.7*	*44.6*	*+8*	*+21%*	*+19%*
Adjusted[2] EBITDA[1]	**88.7**	**103.0**	**+14**	***+16%***	***+15%***
Adjusted[2] EBITDA[1] margin	*32%*	*33%*	*+179 bps*		
EBITDA[1]	**86.8**	**99.8**	**+13**	***+15%***	***+13%***
EBITDA[1] margin	*31%*	*32%*	*+142 bps*		
Adjusted[2] EBIT	**66.8**	**79.6**	**+13**	***+19%***	
Adjusted[2] EBIT margin	*24%*	*26%*	*+200 bps*		
EBIT	**55.9**	**67.0**	**+11**	***+20%***	
EBIT margin	*20%*	*22%*	*+182 bps*		
Adjusted[2] net profit	**50.6**	**53.6**	**+3**	***+6%***	
Adjusted[2] Net profit on Revenues	*18%*	*17%*	*-66 bps*		
Net profit	**38.3**	**42.2**	**+4**	***+10%***	
Net profit on Revenues	*14%*	*14%*	*+4 bps*		

[1] *EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance. Since the composition of EBITDA is not regulated by the reference accounting standards, the criterion of determination applied by the Group may not be homogeneous with that adopted by other operators and/or groups and therefore may not be comparable.*

[2] *With reference to the indicators Adjusted Gross Margin, Adjusted EBITDA, Adjusted EBIT, and Adjusted Net Income, please refer to the table at the end of this Press Release.*

Amounts in millions of euros	9 months		change		
	2025	2026	amount	% @ current	% @ CER
Revenues	**899.7**	**909.6**	**+10**	**+1%**	**+3%**
Immunodiagnostics	*617.6*	*632.4*	*+15*	*+2%*	*+3%*
Molecular Diagnostics	*154.2*	*147.4*	*-7*	*-4%*	*-1%*
Licensed Technologies	*127.9*	*129.8*	*+2*	*+2%*	*+5%*
Adjusted[2] EBITDA[1]	**304.0**	**297.3**	**-7**	**-2%**	**-1%**
Adjusted[2] EBITDA[1] margin	*34%*	*33%*	*-111 bps*		
EBITDA[1]	**290.6**	**287.9**	**-3**	**-1%**	**+0%**
EBITDA[1] margin	*32%*	*32%*	*-64 bps*		
Adjusted[2] EBIT	**236.4**	**228.2**	**-8**	**-3%**	
Adjusted[2] EBIT margin	*26%*	*25%*	*-120 bps*		
EBIT	**194.1**	**192.0**	**-2**	**-1%**	
EBIT margin	*22%*	*21%*	*-46 bps*		
Adjusted[2] net profit	**177.1**	**159.0**	**-18**	**-10%**	
Adjusted[2] Net profit on Revenues	*20%*	*17%*	*-220 bps*		
Net profit	**137.1**	**126.0**	**-11**	**-8%**	
Net profit on Revenues	*15%*	*14%*	*-139 bps*		

COMMENTS ON ECONOMIC RESULTS

REVENUES: Q3 at **€308 million,** up 8% *at constant exchange rates* compared with Q3 2025 (+10% *at current exchange rates*, benefiting from a positive FX impact of €5 million), driven by the acceleration of all business lines, in line with the Company's 2026 Guidance.

For the first nine months of 2026, revenues reached **€910 million**, representing +3% growth *at constant exchange rates* compared with the same period of 2025 (+1% at current exchange rates, reflecting a negative foreign exchange impact of €15 million).

Revenue performance by business line was as follows:

- **Immunodiagnostics:** Q3 2026 at **€213 million,** up 5% *at constant exchange rates* compared with the same period of the previous year (+7% *at current exchange rates*), with a positive FX impact of €3 million.

  The CLIA franchise continued to demonstrate positive business momentum, with quarterly performance primarily supported by the Company's direct European markets and the North American market. Excluding the contribution from China, growth in Q3 2026 reached +6% *at constant exchange rates*, following a trajectory consistent with management expectations.

  In the first nine months of 2026, revenues amounted to **€632 million**, up 3% *at constant exchange rates* compared with the first nine months of 2025 (+2% at current exchange rates, reflecting a negative FX impact of €6 million).

- **Molecular Diagnostics:** Q3 2026 at **€51 million**, up 11% *at constant exchange rates* (+13% *at current exchange rates*, benefiting from a positive FX impact of €1 million) and showing a significant acceleration compared with previous quarters.

  The performance was driven by the strong growth of the automated multiplexing platforms (Verigene and LIAISON PLEX), which increased by 36% *at constant exchange rates* compared with Q3 2025. This result is particularly noteworthy as it does not yet include contributions from the flu season and reflects the rapid expansion of the new business generated by the LIAISON PLEX platform, also supported by the recent commercial launch of the Gastrointestinal Panel. Specialty testing on the LIAISON MDX low-plex molecular platform also continued to deliver positive performance, growing 21% *at constant exchange rates*.

  In the first nine months of 2026, revenues totaled **€147 million**, down 1% *at constant exchange rates* compared with the first nine months of 2025 (-4% *at current exchange rates*, with a negative FX impact of €5 million). The result for the period continued to be negatively affected by the weak flu season that impacted the respiratory testing business during the first quarter of 2026.

- **Licensed Technologies:** Q3 2026 revenues amounted to **€45 million,** up 19% *at constant exchange rates* compared with

the same period of the previous year (+21% at *current exchange rates*, benefiting from a positive FX impact of €1 million).

Growth was supported by the timing of shipments to commercial partners and by strong signs of recovery in the Life Science & Pharma segment, which delivered double-digit growth (+21% *at constant exchange rates* in Q3 2026 compared with the same period of the previous year).

For the first nine months of 2026, revenues amounted to **€130 million**, up 5% at constant exchange rates compared with the first nine months of 2025 (+2% at current exchange rates), reflecting a negative foreign exchange impact of €4 million.

The following is the revenue performance by geographic area:

- **North America Direct:** Q3 2026 revenues amounted to **€157 million**, up 10% *at constant exchange rates* (+12% *at current exchange rates*).

  The Immunodiagnostics business maintained a solid growth trajectory during the quarter (+5% *at constant exchange rates*; +7% *at current exchange rates*), driven by the strong performance of specialty CLIA assays and the continued success of the Company's U.S. hospital strategy. The Molecular Diagnostics franchise delivered double-digit growth (+13% *at constant exchange rates*; +15% *at current exchange rates*), supported by both the specialty testing menu on the LIAISON MDX low-plex platform (+24% *at constant exchange rates* compared with Q3 2025) and the increasing contribution from the automated multiplexing platforms (Verigene and LIAISON PLEX), which grew 35% *at constant exchange rates* versus Q3 2025.

  For the first nine months of 2026, revenues totaled **€452 million**, up 3% *at constant exchange rates* compared with the first nine months of 2025 (flat *at current exchange rates*), reflecting a negative foreign exchange impact of €17 million.

- **Europe Direct:** Q3 2026 revenues amounted to **€107 million**, up 9% both *at constant exchange rates* and *at current exchange rates*, confirming the strong performance of the Immunodiagnostics business during the quarter. For the first nine months of 2026, revenues totaled **€329 million**, up 4% both at constant exchange rates and at current exchange rates compared with the first nine months of 2025.

- **Rest of the World:** Q3 2026 revenues amounted to **€44 million**, up 1% *at constant exchange rates* (+6% *at current exchange rates*). Growth was driven by the Company's key direct markets, excluding China, and was supported in particular by the strong performance of Latin America and Australia, both of which delivered double-digit growth compared with the same period of the previous year. This positive performance was partially offset by weaker results in the APAC region, particularly in the Middle East. China, while showing a slight improvement compared with previous quarters, recorded a revenue decline of approximately 12% at constant exchange rates. For the first nine months of 2026, revenues totaled **€128 million**, down 2% *at constant exchange rates* compared with the first nine months of 2025 (-1% *at current exchange rates*, reflecting a positive foreign exchange impact of €2 million).

ADJUSTED GROSS PROFIT: €198 million in Q3 2026, representing 64% of revenues, benefiting from the solid business performance described above. For the first nine months of 2026, Adjusted Gross Profit totaled **€588 million**, up 1% at *constant exchange rates* compared with the first nine months of 2025 (flat *at current exchange rates*), reflecting a negative foreign exchange impact of €9 million. Adjusted Gross Margin represented 65% of revenues, both *at constant* and *current exchange rates.*

EBITDA[1] **ADJUSTED**[2] amounted to **€103 million** in Q3 2026, representing 34% of revenues *at constant exchange rates,* confirming the positive business performance and remaining in line with expectations. For the first nine months of 2026, adjusted EBITDA totaled €297 million, down 1% *at constant exchange rates* compared with the first nine months of 2025 (-2% *at current exchange rates*), reflecting a negative foreign exchange impact of €4 million. Adjusted EBITDA margin stood at 33% of revenues, both *at constant and current exchange rates*. The slight year-on-year decline primarily reflects the planned investments made to strengthen the U.S. Commercial organization in support of the launch of the LIAISON NES platform.

ADJUSTED[2] **EBIT**: Adjusted EBIT amounted to **€80 million** in Q3 2026, representing 26% of revenues. For the first nine months of 2026, Adjusted EBIT totaled €228 million, down 2% *at constant exchange rates* compared with the first nine months of 2025 (-3% *at current exchange rates*), reflecting a negative foreign exchange impact of €2 million. Adjusted EBIT represented 25% of revenues both *at constant* and *current exchange rates*.

NET FINANCIAL EXPENSES ADJUSTED: Adjusted net financial expenses amounted to **€14 million** in the first nine months of 2026, compared with €1 million of net financial expenses in the first nine months of 2025. The increase was mainly attributable

to lower interest income on cash investments, the costs associated with the share buyback program, and higher interest expenses on bank borrowings and the Group's credit facilities.

ADJUSTED[2] NET PROFIT: amounted to **€54 million** in Q3 2026, representing 17% of revenues. For the first nine months of 2026, Adjusted net profit totaled **€159 million**, representing 17% of revenues. The €18 million decrease (-10%) compared with the first nine months of 2025 primarily reflects the increase in net financial expenses described above.

COMMENT ON FINANCIAL RESULTS

CONSOLIDATED NET FINANCIAL DEBT: **-€782 million** as of September 30, 2026, compared with **-€580 million** as of December 31, 2025. The €202 million change was primarily driven by €237 million cash outflows incurred during the first nine months of 2026 in connection with the ongoing share buyback program, as well as €65 million in dividend payments.

FREE CASH FLOW[3]: **€127 million** in the first nine months of 2026, compared with €161 million in the first nine months of 2025. The result reflects the Group's continued solid cash generation, supported in particular by the strong business performance delivered in Q3 2026, as previously described. This was partially offset by an increase in inventories to support the upcoming launch of the **LIAISON NES** platform.

BUSINESS HIGHLIGHTS

IMMUNODIAGNOSTICS

- Diasorin receives FDA Clearance for the First Fully Automated Laboratory-Based Serology Assays for Human Parvovirus B19 IgM and Human Parvovirus B19 IgG on the LIAISON XL Platform.

MOLECULAR DIAGNOSTICS

- Diasorin receives CE certification under IVDR for the LIAISON PLEX Gastrointestinal Flex Assay, expanding customizable syndromic testing to Europe

OTHER SIGNIFICANT EVENTS

On October 5, 2026, the share buyback program authorized by the Shareholders' Meeting held on January 27, 2026 was successfully completed. The program, aimed at the subsequent cancellation of the repurchased shares without reducing the share capital, was launched to enhance shareholder remuneration and provided for a maximum aggregate consideration of €250 million and, in any event, no more than 4.5 million Diasorin shares, representing approximately 8% of the Company's share capital.

Under the program, Diasorin S.p.A. acquired a total of 3,790,952 treasury shares, corresponding to 6.78% of the share capital, for an aggregate consideration of €249,999,986.67.

Following the completion of the purchases and taking into account the treasury shares already held in portfolio, Diasorin S.p.A. now holds 6,683,050 treasury shares, representing 11.95% of the Company's share capital.

FY 2026 GUIDANCE AT 2025 CER

In light of the first nine months of 2026 results, which were in line with expectations, the Company confirms its Guidance for the full year 2026:

- **REVENUES**: *approx. +5%/+6%*
- **ADJUSTED[1] EBITDA[2] MARGIN**: *approx. 32%/33%*

***

Mrs. Teresa Cervino, the Officer in charge of preparing the Company's financial reports and also responsible for the certification pursuant to paragraph 5-ter in relation to sustainability reporting, declares, pursuant to Article 154-bis, paragraph 2, of Legislative Decree No. 58/1998 (the "Consolidated Law on Finance"), that, based on the controls performed, the accounting information contained in this press release corresponds to the documental results, accounting books and records.

[3] *Free Cash Flow equals net cash flow generated from operating activities including uses for investment and before payment of interest and acquisitions of companies and businesses.*

***

This press release is available to the public at the registered office of the Company and is also published on the Company's website (www.diasorin.com) under the section "Investors - Financial Corner - Press Releases" and on the centralized storage system named eMarket STORAGE at www.emarketstorage.com.

***

The first 9 months 2026 results will be presented to the financial community during a conference call on Thursday November 12, 2026, at 4:00 PM CET.

To participate in the conference call, dial the following numbers:

- From Italy + 39 02 8020911
- From U.K. +44 1212 818004
- From U.S.A. +1 718 7058796

Presentation slides will be made available under the section "Investors - Financial Corner - Presentations" on the Company's website (www.diasorin.com) and on the centralized storage system named eMarket STORAGE at www.emarketstorage.com prior to the beginning of the conference call.

***

Annex: Financial statements not subject to audit by the Group's Independent Auditors.

ANNEXES

CONSOLIDATED INCOME STATEMENT

Amounts in millions of euros	Q3		Change	
	2025	2026	amount	%
Net Revenues	**280.4**	**308.0**	**+28**	***+10%***
Cost of sales	(99.4)	(110.6)	-11	*+11%*
Gross profit	**181.0**	**197.4**	**+16**	***+9%***
	65%	*64%*	*-45 bps*	
Sales and marketing expenses	(69.4)	(74.3)	-5	*+7%*
Research and development costs	(22.8)	(22.7)	+0	*-1%*
General and administrative expenses	(30.2)	(30.2)	-0	*+0%*
Total operating expenses	**(122.4)**	**(127.2)**	**-5**	***+4%***
	44%	*41%*	*-235 bps*	
Other operating income (expense)	(2.7)	(3.3)	-1	*+19%*
non recurring amount	*(0.9)*	*(1.9)*	-1	*n.m.*
EBIT	**55.9**	**67.0**	**+11**	***+20%***
	20%	*22%*	*+182 bps*	
Net financial income (expense)	(5.7)	(9.5)	-4	*+65%*
Profit before taxes	**50.2**	**57.5**	**+7**	***+15%***
Income taxes	(11.8)	(15.3)	-3	*+29%*
Net result	**38.3**	**42.2**	**+4**	***+10%***
EBITDA[1]	**86.8**	**99.8**	**+13**	***+15%***
	31%	*32%*	*+142 bps*	

Amounts in millions of euros	9 months		Change	
	2025	2026	amount	%
Net Revenues	**899.7**	**909.6**	**+10**	***+1%***
Cost of sales	(312.8)	(322.8)	-10	*+3%*
Gross profit	**586.9**	**586.8**	**-0**	***-0%***
	65%	*65%*	*-73 bps*	
Sales and marketing expenses	(211.9)	(221.7)	-10	*+5%*
Research and development costs	(70.0)	(69.4)	+1	*-1%*
General and administrative expenses	(91.6)	(91.4)	+0	*-0%*
Total operating expenses	**(373.4)**	**(382.6)**	**-9**	***+2%***
	42%	*42%*	*+55 bps*	
Other operating income (expense)	(19.4)	(12.2)	*+7*	*-37%*
non recurring amount	*(11.0)*	*(6.4)*	*+5*	*-42%*
EBIT	**194.1**	**192.0**	**-2**	***-1%***
	22%	*21%*	*-46 bps*	
Net financial income (expense)	(12.5)	(23.0)	-11	*+84%*
Profit before taxes	**181.6**	**169.0**	**-13**	***-7%***
Income taxes	(44.6)	(43.1)	+1	*-3%*
Net result	**137.1**	**126.0**	**-11**	***-8%***
EBITDA[1]	**290.6**	**287.9**	**-3**	***-1%***
	32%	*32%*	*-64 bps*	

REVENUES BY TECHNOLOGY

% on Net Revenues	Q3		Change
	2025	2026	
Immunodiagnostics	71%	69%	-180 bps
Molecular Diagnostics	16%	17%	+43 bps
Licensed Technologies	13%	14%	+138 bps

% di incidenza sul fatturato	9 months		Change
	2025	2026	
Immunodiagnostics	69%	70%	+113 bps
Molecular Diagnostics	17%	16%	-109 bps
Licensed Technologies	14%	14%	-4 bps

REVENUES BY GEOGRAPHY

Amounts in millions of euros	Q3		Change		
	2025	2026	amount	%	
				@ current	@ CER
North America Direct	140	157	+16	*+12%*	*+10%*
% on total revenues	*50%*	***51%***			
Europe Direct	99	107	+9	*+9%*	*+9%*
% on total revenues	*35%*	***35%***			
Rest of the World	41	44	+3	*+6%*	*+1%*
% on total revenues	*15%*	***14%***			
Total	**280**	**308**	**+28**	***+10%***	***+8%***

Amounts in millions of euros	9 months		Change		
	2025	2026	amount	%	
				@ current	@ CER
North America Direct	454	452	-1	*-0%*	*+3%*
% on total revenues	*50%*	***50%***			
Europe Direct	317	329	+12	*+4%*	*+4%*
% on total revenues	*35%*	***36%***			
Rest of the World	129	128	-1	*-1%*	*-2%*
% on total revenues	*14%*	***14%***			
Total	**900**	**910**	**+10**	***+1%***	***+3%***

CONSOLIDATED BALANCE SHEET

Amounts in millions of euros	***12/31/2025***	***30/09/2026***	***Change***
Goodwill and intangibles assets	1,790.0	1,828.7	+39
Property, plant and equipment	255.9	274.9	+19
Other non-current assets	42.3	41.6	-1
Net working capital	325.2	371.1	+46
Other non-current liabilities	(256.6)	(267.9)	-11
Net Invested Capital	**2,156.6**	**2,248.4**	**+92**
Net Financial Debt	**(579.8)**	**(781.7)**	**-202**
Total shareholders' equity	**1,576.8**	**1,466.7**	**-110**

CONSOLIDATED STATEMENT OF CASH FLOWS

Amounts in millions of euros	Q3	
	2025	**2026**
Cash and cash equivalents at the beginning of the period	**173.1**	**120.8**
Cash provided by operating activities	114.6	96.5
Cash provided/(used) in investing activities	(80.1)	(28.7)
Cash provided/(used) in financing activities	(59.8)	(80.3)
Net change in cash and cash equivalents before investments in financial assets	**(25.2)**	**(12.5)**
Net change in cash and cash equivalents	**(25.2)**	**(12.5)**
Cash and cash equivalents at the end of the period	**147.8**	**108.3**

Amounts in millions of euros	9 months	
	2025	**2026**
Cash and cash equivalents at the beginning of the period	**344.3**	**165.8**
Cash provided by operating activities	259.6	205.8
Cash provided/(used) in investing activities	(107.8)	(41.6)
Cash provided/(used) in financing activities	(348.2)	(221.7)
Net change in cash and cash equivalents before investments in financial assets	**(196.4)**	**(57.5)**
Net change in cash and cash equivalents	**(196.4)**	**(57.5)**
Cash and cash equivalents at the end of the period	**147.8**	**108.3**

OVERVIEW OF THE GROUP'S OPERATING PERFORMANCE AND FINANCIAL POSITION

This press release presents and comments on certain financial indicators that are not identified in the IFRS. These indicators, which are described below, are used to comment on the Group's business performance, in compliance with the requirements of Consob communication of 28 July 2006 (DEM 6064293), as subsequently amended and supplemented (Consob communication 0092543 of 3 December 2015, which incorporates the ESMA Guidelines ESMA/2015/1415).

The alternative performance indicators listed below should be used to supplement the information required by IFRS to help readers of the press release gain a more comprehensive understanding of the Group's economic, financial and operating position. These measures exclude one-off items related to non-recurring events, which mainly include costs associated with corporate restructuring and organizational efficiency programs following the launch of new platforms, amortization arising from the *purchase price allocation* of Luminex, and financial expenses related to the financing of the acquisition, including the related tax effects.

It should be noted that the calculation of these *adjusted* indicators could differ from those used by other companies.

9M'26 ADJUSTED INDICATOR

Amounbts in millions of euros	Gross Profit	EBITDA	EBIT	Net Result
Financial Statements Measures	**586.8**	**287.9**	**192.0**	**126.0**
% on Revenues	*65%*	*32%*	*21%*	*14%*
Adjustments				
"One-off" costs related to non recurring events	1.4	9.3	8.4	7.7
Depreciation of Luminex intangibles identified in the Purchase Price Allocation	-	-	27.7	27.7
Financial charges relating to debt instruments and to the convertible bond issued to finance the acquisition of Luminex net of hedging effects	-	-	-	8.9
Total adjustments before tax effect	**1.4**	**9.3**	**36.1**	**44.3**
Fiscal effect on adjustments	-	-	-	(11.2)
Totale aggiustamenti	**1.4**	**9.3**	**36.1**	**33.1**
Adjusted Measures	**588.2**	**297.3**	**228.2**	**159.0**
% on Revenues	*65%*	*33%*	*25%*	*17%*

9M'25 ADJUSTED INDICATORS

Amounts in millions of euros	Gross Profit	EBITDA	EBIT	Net Result
Financial Statements Measures	**586.9**	**290.6**	**194.1**	**137.1**
% on Revenues	*65%*	*32%*	*22%*	*15%*
Adjustments				
"One-off" costs related to non recurring events	2.9	13.4	14.7	14.7
Depreciation of Luminex intangibles identified in the Purchase Price Allocation	-	-	27.6	27.6
Financial charges relating to debt instruments and to the convertible bond issued to finance the acquisition of Luminex net of hedging effects	-	-	-	11.4
Total adjustments before tax effect	**2.9**	**13.4**	**42.3**	**53.7**
Fiscal effect on adjustments	-	-	-	(13.7)
Total Adjustments	**2.9**	**13.4**	**42.3**	**40.0**
Adjusted Measures	**589.8**	**304.0**	**236.4**	**177.1**
% on Revenues	*66%*	*34%*	*26%*	*20%*

(*) To improve comparability, the adjusted income statement metrics for the first half of 2025 have been restated to reflect a different timing allocation of the operating costs of the Chinese subsidiary following its reorganization, which were originally fully recognized in the fourth quarter of 2025. These costs have been reallocated throughout 2025 based on the period to which they relate.

OPERATING PERFORMANCE IN 9M'26 AND COMPARISON WITH9M'25

Amounts in millions of euros	09/30/2025	% on Revenues	09/30/2026	% on Revenues
Net Revenues	899.7	100%	909.6	100%
Cost of Sales	(312.8)	35%	(322.8)	35%
Gross Profit	**586.9**	**65%**	**586.8**	**65%**
Adjusted[2] Gross Profit	**589.8**	**66%**	**588.2**	**65%**
Total operating costs	(392.8)	44%	(394.8)	43%
EBIT	**194.1**	**22%**	**192.0**	**21%**
Adjusted[2] EBIT	**236.4**	**26%**	**228.2**	**25%**
Net financial income (expense)	(12.5)	1%	(23.0)	3%
Profit before taxes	**181.6**	**20%**	**169.0**	**19%**
Income taxes	(44.6)	5%	(43.1)	5%
Net Profit	**137.1**	**15%**	**126.0**	**14%**
Adjusted[2] Net Profit	**177.1**	**20%**	**159.0**	**17%**
EBITDA[1]	**290.6**	**32%**	**287.9**	**32%**
Adjusted[2] EBITDA[1]	**304.0**	**34%**	**297.3**	**33%**

For additional information, please contact:

INVESTOR RELATIONS

Margherita Sacerdoti
Senior Director Investor Relations & ESG
margherita.sacerdoti@diasorin.com